• 29.06.2018 – 01:02

  Astellas Pharma Europe Limited

  Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

  Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

  more

• 24.02.2016 – 01:02

  Astellas Pharma Europe Limited

  Britain Facing Social Care 'Time-bomb' with Thousands of People Underprepared to Look After Themselves in Old Age

  Chertsey, England (ots/PRNewswire) - Experts say the knock-on effect of lack of planning for later life, as highlighted in poll conducted for this year's ASTELLAS INNOVATION DEBATE[TM],will further impact upon stretched NHS resources Results from a new survey for the annual Astellas Innovation Debate have ...

  more

• 24.03.2015 – 12:26

  Astellas Pharma Europe Limited

  Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

  London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...

  more

• 22.10.2013 – 13:00

  Astellas Pharma Europe Limited

  Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer

  Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...

  more

• 30.08.2011 – 09:04

  Astellas Pharma Europe Limited

  Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe

  Staines, England (ots/PRNewswire) - Astellas Pharma Inc. [http://www.astellas.com/en/corporate ] today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. ...

  more

• 20.05.2011 – 16:37

  Astellas Pharma Europe Limited

  Astellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA

  Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ...

  more

• 20.04.2010 – 07:03

  Astellas Pharma Europe Limited

  Urology and Transplantation Will Drive Future Growth as Astellas Begins Move into Oncology

  London, April 20, 2010 (ots/PRNewswire) - Today, on the fifth anniversary since its formation, Astellas Pharma Europe has confirmed that it will continue its emphasis on transplantation and urology while moving towards a new vision to build a strong presence in oncology. Astellas has shown robust growth since its creation, expanding its reach into new therapeutic areas ...

  more

• 30.04.2007 – 08:04

  Astellas Pharma Europe Limited

  Advagraf(R) Now Approved Across Europe as a Once-Daily Immunosuppressant in Organ Transplantation

  London (ots/PRNewswire) - Astellas announced today that the European Commission has approved the immunosuppressant Advagraf(R) (generic name: tacrolimus, prolonged release) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection ...

  more